Core Viewpoint - Dongyangguang Pharmaceutical (600673) has seen a significant stock price increase following the approval of its new drug HECN30227 for clinical trials in chronic hepatitis B treatment, indicating positive market sentiment and potential growth opportunities for the company [1] Group 1: Stock Performance - Dongyangguang Pharmaceutical's stock rose nearly 5% during trading, with a current increase of 3.25%, reaching HKD 48.88 [1] - The trading volume was reported at HKD 23.2866 million, reflecting active investor interest [1] Group 2: Regulatory Approvals - The National Medical Products Administration (NMPA) of China has approved Dongyangguang Pharmaceutical's self-developed first-class new drug, HECN30227, for clinical trials targeting chronic hepatitis B [1] - Additionally, the company has received approval for its Fingolimod Hydrochloride Capsules, marking it as the first domestic generic version, which disrupts the original manufacturer's market dominance [1]